Text Size

Simvatstatin Used to Treat Pulmonary Hypertension

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2007 by Capital Medical University.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Capital Medical University
ClinicalTrials.gov Identifier:
NCT00538044
First received: October 1, 2007
Last updated: NA
Last verified: September 2007
History: No changes posted
  Purpose

we try to use simvastatin in the treatment of advanced pulmoary hypertension secondary to congenital heart disease or chronic pulmonary embolism before and after the operation.


Condition Intervention Phase
Hypertension, Pulmonary
 Drug: simvastatin
 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Official Title: the Clinical Research Using Simvastatin as a Medication to Treat Advanced Secondary Pulmonary Hypertension

Resource links provided by NLM:

Drug Information available for: Simvastatin
U.S. FDA Resources

Further study details as provided by Capital Medical University:

Primary Outcome Measures:
  • the simvastatin can alleviate pulmonary hypertension
  • pulmonary pressure

Secondary Outcome Measures:
  • simvastatin can highten the perioperative and long term survaval rate and the living quality

Study Start Date: January 2009
Estimated Study Completion Date: January 2012
Arms Assigned Interventions
Experimental: 1simvastatin group
before the operation, the patient start the simvastatin medication on the dosage of 40mg per day
 Drug: simvastatin
medication with simvastation on the dosage of 40mg per day before the operation and all the time after the operation
Other Name: simvastatin
No Intervention: 2contral group
just do routin operation with no use of simvastatin, other medication is exact the same as the simvastatin group

Detailed Description:

advanced pulmonary hypertension is refractory to the medication in use nowaday, especially pulmonary hypertension secondary to congenital heart disease or chronic pulmonary embolism.It is revealed that statins may intefere the pathogenisis of the pulmonary hypertension in many key poing, such as improving apotosis or inhiting the proliferation of pulmonary vascular smooth muscle cell. so we try to use simvastatin in the treatment of advanced pulmoary hypertension secondary to congenital heart disease or chronic pulmonary embolism before and after the operation.

  Eligibility

Ages Eligible for Study:   12 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • pasp>50mmHg

Exclusion Criteria:

  • pasp<50mmhg
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00538044

Contacts
Contact: Huili Gan, MD,Ph.D. 13001277863 ganhuili@hotmail.com

Locations
China
Beijing Anzhen Hospital Not yet recruiting
Beijing, China, 100029
Contact: Huili Gan, MD, Ph.D.     861013001277863     ganhuili@hotamail.com    
Sponsors and Collaborators
Capital Medical University
Investigators
Study Chair: Huili Gan, MD,Ph.D. Beijing Anzehn Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00538044     History of Changes
Other Study ID Numbers: Gan1, Anzhen1
Study First Received: October 1, 2007
Last Updated: October 1, 2007
Health Authority: China: Ethics Committee

Keywords provided by Capital Medical University:
pulmonary hypertension
simvastatin
advanced pulmonary hypertension secondary to congenital heart disease
advanced pulmonary hypertension secondary to chronic pulmonary embolism

Additional relevant MeSH terms:
Hypertension
Hypertension, Pulmonary
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Simvastatin
Hypolipidemic Agents
 Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Lipid Regulating Agents
Therapeutic Uses
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Enzyme Inhibitors

ClinicalTrials.gov processed this record on May 19, 2013